GH
Guardant Health, Inc. · Healthcare
87.17
6.11%(−5.67)
Pre-MarketLast Updated: — ET
52W L: $36.3652W H: $120.74
Guardant Health, Inc. · Healthcare
Monroe Terilyn J.
officer: Chief People Officer
3,832 SH @ $92.68
2026-04-06
Saia John G.
officer: Chief Legal Officer
5,895 SH @ $0.00
2026-04-01
Saia John G.
officer: Chief Legal Officer
2,925 SH @ $0.00
2026-04-01
Saia John G.
officer: Chief Legal Officer
6,013 SH @ $91.15
2026-04-01
Saia John G.
officer: Chief Legal Officer
1,667 SH @ $0.00
2026-04-01
Saia John G.
officer: Chief Legal Officer
974 SH @ $0.00
2026-04-01
Saia John G.
officer: Chief Legal Officer
2,925 SH @ $0.00
2026-04-01
Saia John G.
officer: Chief Legal Officer
5,895 SH @ $0.00
2026-04-01
Guardant Health, Inc. (NASDAQ: GH - Get Free Report) insider Terilyn Monroe sold 3,832 shares of the stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $92.68, for a total value of $355,149.76. Following the transaction, the insider owned 20,990 shares of the company's stock, valued
Guardant Health, Inc. maintains a bullish outlook, driven by strong oncology segment growth and leadership in liquid biopsy testing. GH delivered FY2025 revenue of $982 million, up 33% YoY, with oncology contributing 67.6% of total revenues and 26% YoY growth. Liquid biopsy adoption is accelerating, offering non-invasive cancer diagnostics and supporting GH's revenue momentum and market outperformance.
Capricorn Fund Managers Ltd boosted its holdings in shares of Guardant Health, Inc. (NASDAQ: GH) by 197.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 107,787 shares of the company's stock after acquiring an additional 71,587 shares
Guardant Health, Inc. (NASDAQ: GH - Get Free Report) has received an average rating of "Moderate Buy" from the twenty-two analysts that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and twenty have assigned a buy recommendation to the company. The
PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that real-world evidence generated from Guardant's InfinityAI contributed to the recent approval of ENHERTU® (trastuzumab deruxtecan), developed and commercialized by Daiichi Sankyo (TSE:4568) in Japan, for the treatment of patients with HER2-positive (HER2 [ERBB2] gene amplification or immunohistochemistry [IHC] 3+) advanced or recurrent solid cancers refractory or into.
Connective Portfolio Management LLC bought a new stake in Guardant Health, Inc. (NASDAQ: GH) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 7,000 shares of the company's stock, valued at approximately $715,000. Guardant Health accounts for about 1.3% of Connective